FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

10 Observations in Shilpa Medicare Inspection

[ Price : $8.95]

FDA releases the FDA-483 with 10 observations from an inspection at Indias Shilpa Medicare Limited.

Antibiotic Susceptibility Test Guidance

[ Price : $8.95]

FDA issues a guidance on fulfilling new labeling requirements for susceptibility test interpretive criteria for prescription syste...

OMB Asked to Extend Info Collection on FDA Drug Communications

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection extension request for Data To Support Drug Product Communicati...

Hospitals Suggest Ways to Improve Drug Compounding

[ Price : $8.95]

The American Hospital Association urges FDA to take steps to reduce the regulatory burden on hospitals involving compounded drugs ...

Stakeholders Ask REMS Guidance Changes

[ Price : $8.95]

Four drug stakeholders ask FDA to revise its draft guidance on REMS format and content.

FDA Draft Guide on NDA/BLA Refuse to File Actions

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Refuse to File: NDA and BLA Submissions to CDER.

Tremeau Gains FDA Agreement to Develop Withdrawn Drug

[ Price : $8.95]

Tremeau Pharmaceuticals says it has recently reached agreement with FDA on the development requirements to support an NDA for TRM-...

Web Site Established on Susceptibility Test Criteria

[ Price : $8.95]

Federal Register notice: FDA establishes a Susceptibility Test Interpretive Criteria Web site that is intended to help efficiently...

FDA Approves Boston Scientific Brain Stimulator

[ Price : $8.95]

FDA approves a Boston Scientific PMA for the Vercise Deep Brain Stimulation System and its use for treating symptoms of Parkinsons...

Use New Regulations to Ease Regulatory Burden: MIWG

[ Price : $8.95]

The Medical Information Working Group says there are instances in which industrys regulatory burden could be eased through additio...